Universitaetsklinikum Tuebingen AöR — Sponsor Intelligence | 28 EU Trials

Filter these 28 trials by condition, phase, country and more.

Open in Search →

28 Registered trials

18 Recruiting

9 Completed trials

12 Countries active

28 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I

Phase I (FiH)

Phase III: 4 Phase II: 11 Phase I/II: 3 Phase IV: 1 Phase I: 5 Phase I (Other): 1 Phase I (FiH): 3

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

9 of 9 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Parkinson's disease 2 Retinopathy of prematurity 2 Myelodysplastic syndrome 1 Prostate cancer recurrent 1 Alveolar rhabdomyosarcoma 1 Encephalopathy neonatal 1 Malignant melanoma 1 Death neonatal 1 Neonatal asphyxia 1 Synovial sarcoma 1 Chronic kidney disease 1 Glioblastoma 1

Top IMPs

ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE 8 CONTAINING THE HUMAN CNGA3 GENE UNDER THE CONTROL OF A CONE ARRESTIN PROMOTER 1 ALLOPURINOL SODIUM 1 AMANTADINE HEMISULFATE 1 BEVACIZUMAB 1 CALCIUM FOLINATE PENTAHYDRATE 1 DAPAGLIFLOZIN 1 DNAJB1-PRKACA TRIFLUORACETATE 1 ENTACAPONE, LEVODOPA, CARBIDOPA MONOHYDRATE 1 FLUDARABINE PHOSPHATE PH. EUR. 1 FLUOROURACIL 1 KETAMINE HYDROCHLORIDE 1 MB-CART2219.1 1

All trials

28 total

A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in part… Pending

2024-513496-40-00 Phase II 6 countries PRASINEZUMAB
Prospective phase I/II trial of an individualized peptide vaccine in pediatric and AYA patients with metastasized fusion-driven sarcomas fol… Recruiting

2024-511337-35-00 Phase II 1 country PERVI-FUS, PERVI-NEO, 11902A
Safety, Tolerability and Efficacy against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults Recruiting

2024-518273-34-02 Phase I (Other) 1 country
Safety and Feasibility of a Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning before Allogeneic Stem Cell Transplantatio… Recruiting

2025-521372-62-00 Phase II 1 country FLUDARABINE PHOSPHATE PH. EUR.; TREOSULFAN; VENETOCLAX
Antimalarial prophylactic efficacy of a weekly dose atovaquone-proguanil Recruiting

2024-518884-36-00 Phase II 1 country PLASMODIUM FALCIPARUM, STRAIN NF54, SPOROZOITES; PROGUANIL HYDROCHLORIDE, ATOVAQ…
INITIATE-LECIG: Intestinal levodopa + entacapone therapy (Lecigon®) to counteract dopaminergic desensitization and neuropsychiatric complica… Recruiting

2025-521048-39-00 Phase III 1 country ENTACAPONE, LEVODOPA, CARBIDOPA MONOHYDRATE
A Phase I dose finding study of MB-CART2219.1 targeting CD19/CD22 in adult and pediatric patients with relapsed/refractory B-cell malignanci… Recruiting

2024-516838-35-00 Phase I 1 country MB-CART2219.1
FusionVAC22_02: DNAJB1-PRKACA fusion transcript-based peptide vaccine for fibrolamellar hepatocellular carcinoma patients and other tumor en… Recruiting

2024-519387-41-00 Phase I 1 country DNAJB1-PRKACA TRIFLUORACETATE
Oral Propranolol for prevention of threshold retinopathy of prematurity Recruiting

2024-511338-10-01 Phase II 1 country
A randomized double-blind placebo-controlled first-in-man single-dose and multiple dose study to evaluate the safety, tolerability and effic… Recruiting

2023-507737-17-00 Phase I 1 country
AML-VAC-XS15-01: Multi-peptide vaccination adjuvanted with the TLR1/2 ligand XS15 in acute myeloid leukemia (AML) patients who have achieved… Recruiting

2023-510316-39-00 Phase I 1 country
PRIDE – PRotective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma Recruiting

2024-514865-20-00 Phase II 1 country BEVACIZUMAB
SGLT2 inhibition in addition to lifestyle intervention and risk for complications in subtypes of patients with prediabetes - a randomized,… Recruiting

2024-512179-11-00 Phase IV 1 country DAPAGLIFLOZIN
A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatr… Recruiting

2024-511336-28-00 Phase I/II 1 country TAFASITAMAB
Pharmacologic treatment augmentation in chronic depression “randomized, controlled, double blinded, phase II study” Recruiting

2024-512478-86-00 Phase II 1 country KETAMINE HYDROCHLORIDE
Phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC 1 in men with biochemical… Recruiting

2024-511430-12-00 Phase I 1 country
Early detection of side effects in patients with metastatic melanoma receiving immune checkpoint inhibitor therapy by investigation of the C… Recruiting

2024-512219-37-00 Phase II 1 country ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM
Intrathecal application of PD-1 antibody in metastatic solid tumors with leptomeningeal disease Recruiting

2024-514068-14-00 Phase I/II 1 country NIVOLUMAB
First in human study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with… Recruiting

2024-512894-29-00 Phase I (FiH) 1 country
A phase I/IIa, dose-finding study to assess the safety and immunogenicity of an Orf virus-based COVID-19 vaccine booster (Prime-2-CoV_Beta) … Ended

2024-511266-36-00 Phase I (FiH) 1 country
Safety and efficacy of a bilateral single subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia in… Ended

2024-515553-17-00 Phase I/II 1 country ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE 8 CONTAINING THE HUMAN CNGA3 GENE UNDER T…
PIGMENT – PDE6A gene therapy for retinitis pigmentosa Ended

2024-517924-20-00 Phase I (FiH) 1 country
A trial funded by the German Federal Ministry for Education and Research (BMBF) to evaluate the effects of closed-loop automatic control of … Ended

2024-511335-10-01 Phase III 1 country
AmaNtadine for NeuroenhancEment in acutE patients Study - A prospective pilot proof of concept phase IIb study in intensive and intermediate… Ended

2024-512333-33-00 Phase II 1 country AMANTADINE HEMISULFATE

Showing 1–24 of 28 trials

← All sponsors A–Z